青蒿素类抗疟药药效的比较及联合用药  

Comparison of efficacy of artemisinin antimalarials and combined use the drugs

作　　者：李佳[1,2] 吴兰鸥[1] 杨照青[2] 

机构地区：[1]昆明医学院药理学教研室,云南昆明650031 [2]昆明医学院寄生虫学教研室,云南昆明650031

出　　处：《中国热带医学》2009年第1期157-159,195,共4页China Tropical Medicine

基　　金：国家自然科学基金资助项目(NO:30560022)

摘　　要：疟疾是全球广泛流行的寄生虫病。恶性疟原虫株对常规抗疟药多已产生耐药性。青蒿素类现作为一线抗疟药用于临床。从现有文献着手,本文综述了恶性疟原虫对抗疟药的抗性现状,比较了恶性疟原虫对青蒿素类药物与喹啉类药物的敏感性,提示青蒿素类药物目前作为首选药应用于临床的优点。疟疾治疗的主要困难是耐药性产生,而联合用药是避免或延缓耐药性产生,提高疗效的有效手段,因此本文还综述了以青蒿素类药物为基础的抗疟药联合用药现状及初步比较,提示以青蒿素为基础的联合用药方案有其他可能的组合。Malaria is a global pandemic parasitic diseases. Plasmodium falciparum is now resistant to conventional antimalarials . Artemisinin combination treatments （ACTs） as a first line drug are now widely used in clinical treatment. The status of resistance of Plasmodium falciparum to antimarials , the sensitivity of P.falciparum to artimisinin antimarials and quinlines and the advantages of artimisinin used in clinical treatment as the first-line drug, are discussed in this paper. Drug resistance is the main difficulty in treatment of malaria and combined use of antimalarials is an effective means to improve the efficacy and delay the occurrence of drug resistance . The paper also reviewed coditions of combined use of artemisinin- based antimalarials.

关 键 词：青蒿素类 抗疟药 联合用药 

分 类 号：R978.61[医药卫生—药品]